Pfizer's pneumonia vaccine for children, Prevnar 13, has been backed by an FDA advisory committee to be used in treating diseases caused by pneumococcus bacteria in adults.
The advisory committee voted 14-1 in favor of using the vaccine in adults and with FDA usually approving products backed by the committee, Prevnar is expected to be approved for treating pneumonia disease among adults.
AdvertisementThe health regulator is said to be considering placing the vaccine on an accelerated approval process and will reach a decision soon on whether to approve the vaccine to be used in adults over 50 years of age.
The vaccine, which was approved in October 2010 for preventing diseases caused by S. pneumoniae serotypes in children, generated over $3.7 billion in sales worldwide and Pfizer revealed that it could generate an additional $1.5 billion annually if it is approved for adults.
PAntibiotic Overuse Pattern in Southeastern United States Worrisome Bubble Man Goes Public to Help His Children Avoid Similar Fate M
You May Also Like